BioMarin Pharmaceutical
Stock Forecast, Prediction & Price Target
BioMarin Pharmaceutical (BMRN) stock Price Target by analysts
$80.2
Potential upside: 40.70%
BioMarin Pharmaceutical price prediction
What is BioMarin Pharmaceutical stock analysts` prediction?
BioMarin Pharmaceutical stock forecast: Based on 5 Wall Street analysts` predicted price targets for BioMarin Pharmaceutical in the last 3 months, the avarage price target is $80.2, with a high forecast of $NaN. The average price target represents a 40.70% change from the last price of $57.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
BioMarin Pharmaceutical stock Price Target by analysts
Full breakdown of analysts given BioMarin Pharmaceutical price targets
BioMarin Pharmaceutical Financial Estimates
BioMarin Pharmaceutical Revenue Estimates
BioMarin Pharmaceutical EBITDA Estimates
BioMarin Pharmaceutical Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.84B N/A | $2.09B 13.52% | $2.41B 15.41% | Avg: $3.07B Low: $2.84B High: $3.24B avg. 27.28% | Avg: $3.42B Low: $3.23B High: $3.58B avg. 11.30% | Avg: $3.78B Low: $3.56B High: $3.95B avg. 10.30% | Avg: $4.17B Low: $3.93B High: $4.36B avg. 10.31% |
Net Income
% change YoY
| $-64.08M N/A | $141.56M 320.91% | $167.64M 18.42% | Avg: $501.80M Low: $101.54M High: $773.46M avg. 199.32% | Avg: $683.44M Low: $210.75M High: $1.05B avg. 36.19% | Avg: $879.22M Low: $813.59M High: $932.13M avg. 28.64% | Avg: $1.15B Low: $1.06B High: $1.22B avg. 30.91% |
EBITDA
% change YoY
| $48.02M N/A | $159.51M 232.14% | $310.28M 94.51% | Avg: $119.60M Low: $110.58M High: $125.88M avg. -61.45% | Avg: $133.13M Low: $125.48M High: $139.29M avg. 11.30% | Avg: $146.84M Low: $138.41M High: $153.64M avg. 10.30% | Avg: $162.00M Low: $152.70M High: $169.50M avg. 10.31% |
EPS
% change YoY
| -$0.35 N/A | $0.76 317.14% | $0.89 17.10% | Avg: $2.59 Low: $0.53 High: $4.04 avg. 191.07% | Avg: $3.39 Low: $1.1 High: $5.5 avg. 30.99% | Avg: $4.59 Low: $4.25 High: $4.87 avg. 35.22% | Avg: $6.01 Low: $5.56 High: $6.37 avg. 30.91% |
Operating Expenses
% change YoY
| $1.45B N/A | $1.57B 7.72% | $1.74B 11.17% | Avg: $1.23B Low: $1.14B High: $1.29B avg. -29.37% | Avg: $1.37B Low: $1.29B High: $1.43B avg. 11.30% | Avg: $1.51B Low: $1.42B High: $1.58B avg. 10.30% | Avg: $1.67B Low: $1.57B High: $1.74B avg. 10.31% |
FAQ
What is BioMarin Pharmaceutical stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 73.77% in 2025-2028.
We have gathered data from 17 analysts. Their low estimate is 101.54M, average is 501.80M and high is 773.46M.
What is BioMarin Pharmaceutical stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 14.80% in 2025-2028.
We have gathered data from 19 analysts. Their low revenue estimate is $2.84B, average is $3.07B and high is $3.24B.
What is BioMarin Pharmaceutical stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 72.05% in 2025-2028.
We have gathered data from 17 analysts. Their low earnings per share estimate is $0.53, average is $2.59 and high is $4.03.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering BioMarin Pharmaceutical stock. The most successful analyst is Olivia Brayer whose win rate is 50%. He has correctly predicted 1/2 price targets.